Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study (Q34596441)

3 August 2017

Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

9

Reed A Omary

1 reference

3 August 2017

Saad M Ibrahim

1

1 reference

3 August 2017

Mary F Mulcahy

2

1 reference

3 August 2017

Robert J Lewandowski

3

1 reference

3 August 2017

Kent T Sato

4

1 reference

3 August 2017

Robert K Ryu

5

1 reference

3 August 2017

Elizabeth J Masterson

6

1 reference

3 August 2017

Steven B Newman

7

1 reference

3 August 2017

Al Benson

8

1 reference

3 August 2017

Riad Salem

10

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

3 August 2017

1 reference

3 August 2017

113

1 reference

3 August 2017

8

1 reference

3 August 2017

2119-2128

1 reference

Treatment options for hepatobiliary and pancreatic cancer

3 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Radioembolization with 90Y microspheres: angiographic and technical considerations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Technical aspects of radioembolization with 90Y microspheres.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Angiographic considerations in patients undergoing liver-directed therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

The epidemiology of cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

What prognostic factors are important for resected intrahepatic cholangiocarcinoma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Role of radiation after operative palliation in cancer of the proximal bile ducts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

The role of chemotherapy in cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23818

7 January 2021

Identifiers

DOI

10.1002/CNCR.23818

1 reference

3 August 2017

1 reference